Nutanix, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q3 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Nutanix, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q3 2015 to Q3 2024.
  • Nutanix, Inc. Net Income (Loss) Attributable to Parent for the quarter ending October 31, 2024 was $29.9M.
  • Nutanix, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending October 31, 2024 was -$79M, a 53.8% increase year-over-year.
  • Nutanix, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$125M, a 51% increase from 2023.
  • Nutanix, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$255M, a 68.1% increase from 2022.
  • Nutanix, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$799M, a 22.9% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$79M $29.9M +$45.8M Aug 1, 2024 Oct 31, 2024 10-Q 2024-12-05
Q2 2024 -$125M -$126M -$113M -849% May 1, 2024 Jul 31, 2024 10-K 2024-09-19
Q1 2024 -$12M -$15.6M +$55.4M +78% Feb 1, 2024 Apr 30, 2024 10-Q 2024-06-10
Q4 2023 -$67.3M $32.8M +$104M Nov 1, 2023 Jan 31, 2024 10-Q 2024-06-10
Q3 2023 -$171M -$15.9M +$83.7M +84.1% Aug 1, 2023 Oct 31, 2023 10-Q 2024-12-05
Q2 2023 -$255M -$13.3M +$138M +91.2% May 1, 2023 Jul 31, 2023 10-K 2024-09-19
Q1 2023 -$393M -$71M +$41M +36.6% Feb 1, 2023 Apr 30, 2023 10-Q 2024-06-10
Q4 2022 -$434M -$70.8M +$44.6M +38.7% Nov 1, 2022 Jan 31, 2023 10-Q 2024-06-10
Q3 2022 -$478M -$99.5M +$321M +76.3% Aug 1, 2022 Oct 31, 2022 10-Q 2024-06-10
Q2 2022 -$799M -$151M +$208M +57.9% May 1, 2022 Jul 31, 2022 10-K 2024-09-19
Q1 2022 -$1.01B -$112M +$11.7M +9.43% Feb 1, 2022 Apr 30, 2022 10-Q 2023-06-02
Q4 2021 -$1.02B -$115M +$172M +59.8% Nov 1, 2021 Jan 31, 2022 10-Q 2023-06-02
Q3 2021 -$1.19B -$420M -$155M -58.5% Aug 1, 2021 Oct 31, 2021 10-Q 2023-06-02
Q2 2021 -$1.04B -$360M -$174M -94% May 1, 2021 Jul 31, 2021 10-K 2023-09-21
Q1 2021 -$861M -$124M +$117M +48.6% Feb 1, 2021 Apr 30, 2021 10-Q 2022-06-02
Q4 2020 -$978M -$287M -$69.8M -32.1% Nov 1, 2020 Jan 31, 2021 10-Q 2022-06-02
Q3 2020 -$909M -$265M -$35.7M -15.6% Aug 1, 2020 Oct 31, 2020 10-Q 2022-06-02
Q2 2020 -$873M -$185M +$8.99M +4.63% May 1, 2020 Jul 31, 2020 10-K 2020-09-23
Q1 2020 -$882M -$241M -$30.9M -14.7% Feb 1, 2020 Apr 30, 2020 10-Q 2021-06-03
Q4 2019 -$851M -$218M -$94.8M -77.2% Nov 1, 2019 Jan 31, 2020 10-Q 2021-06-03
Q3 2019 -$756M -$229M -$135M -143% Aug 1, 2019 Oct 31, 2019 10-Q 2021-06-03
Q2 2019 -$621M -$194M -$107M -122% May 1, 2019 Jul 31, 2019 10-K 2020-09-23
Q1 2019 -$514M -$210M -$124M -145% Feb 1, 2019 Apr 30, 2019 10-K 2020-09-23
Q4 2018 -$390M -$123M -$60.1M -96% Nov 1, 2018 Jan 31, 2019 10-K 2020-09-23
Q3 2018 -$330M -$94.3M -$32.8M -53.3% Aug 1, 2018 Oct 31, 2018 10-K 2020-09-23
Q2 2018 -$297M -$87.4M -$21.2M -32.1% May 1, 2018 Jul 31, 2018 10-K 2019-09-24
Q1 2018 -$276M -$85.7M +$11.2M +11.5% Feb 1, 2018 Apr 30, 2018 10-K 2019-09-24
Q4 2017 -$287M -$62.6M +$13.7M +18% Nov 1, 2017 Jan 31, 2018 10-K 2019-09-24
Q3 2017 -$301M -$61.5M +$78.8M +56.2% Aug 1, 2017 Oct 31, 2017 10-K 2019-09-24
Q2 2017 -$380M -$66.1M -$16.2M -32.5% May 1, 2017 Jul 31, 2017 10-K 2018-09-24
Q1 2017 -$363M -$96.8M -$50M -107% Feb 1, 2017 Apr 30, 2017 10-K 2018-09-24
Q4 2016 -$313M -$76.4M -$43.2M -130% Nov 1, 2016 Jan 31, 2017 10-K 2018-09-24
Q3 2016 -$270M -$140M -$102M -264% Aug 1, 2016 Oct 31, 2016 10-K 2018-09-24
Q2 2016 -$168M -$49.9M May 1, 2016 Jul 31, 2016 10-K 2017-09-18
Q1 2016 -$46.8M Feb 1, 2016 Apr 30, 2016 10-K 2017-09-18
Q4 2015 -$33.2M Nov 1, 2015 Jan 31, 2016 10-K 2017-09-18
Q3 2015 -$38.5M Aug 1, 2015 Oct 31, 2015 10-K 2017-09-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.